< Back to previous page

Project

Understanding and exploiting glycosylation in immunotherapy.

Many vaccine proteins are extensively modified with sugars (glycans), but it has been difficult until recently to produce pure glycoforms of such vaccine proteins. This has obstructed the targeted engineering of the sugar structures for studying and improving vaccine efficacy. New biotechnology being developed at Ghent University overcomes this research bottleneck, which may lead to new vaccines for allergy, flu and worm infections.

Date:1 Jan 2017 →  31 Oct 2021
Keywords:pathway engineering, vaccines, glycosylation
Disciplines:Other engineering and technology, Biological system engineering, Immunology, Microbiology, Other (bio)medical engineering, Industrial biotechnology, Pathophysiology, Molecular and cell biology, Virology, Other biotechnology, bio-engineering and biosystem engineering, Infectious diseases, Vaccines, Vaccinology, Medical biotechnology not elsewhere classified, Veterinary medicine, Laboratory medicine